TY - JOUR
T1 - Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA
AU - Hara, Hideo
AU - Mouri, Akihiro
AU - Yonemitsu, Yoshikazu
AU - Nabeshima, Toshitaka
AU - Tabira, Takeshi
N1 - Funding Information:
Authors are grateful to Dr. Y. Noda at Meijo University, Dr. T. Nagai at Nagoya University, and Dr. M. Inoue at DNAVEC Co. for their kind help in this study. This study was supported in part by a grant ( NIBIO 05-27 ) and by Health and Labor Sci. Res. Grant, Regulatory Sci. Pharmaceut. Med. Devices from the Ministry of Health, Labor and Welfare, Japan; Acad. Front. Project for Private Univ. (2007–2011) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Internat. Res. Project, The Meijo Asian Res. Center ; Grant-in-Aid for Explor. Res. ; Grant-in-Aid for Scientific Res. (B) ; Grant-in-Aid on Priority Areas , and Grant from INSERM-JSPS Joint Res. Project, JSPS .
PY - 2011/10/6
Y1 - 2011/10/6
N2 - Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying Aβ1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to Aβ. When APP transgenic mice (Tg2576) received this vaccine once nasally, the Aβ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of Aβ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the Aβ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.
AB - Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying Aβ1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to Aβ. When APP transgenic mice (Tg2576) received this vaccine once nasally, the Aβ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of Aβ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the Aβ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.
UR - https://www.scopus.com/pages/publications/80053439054
UR - https://www.scopus.com/pages/publications/80053439054#tab=citedBy
U2 - 10.1016/j.vaccine.2011.07.057
DO - 10.1016/j.vaccine.2011.07.057
M3 - Article
C2 - 21803105
AN - SCOPUS:80053439054
SN - 0264-410X
VL - 29
SP - 7474
EP - 7482
JO - Vaccine
JF - Vaccine
IS - 43
ER -
SDG 3 すべての人に健康と福祉を